COSMIC gene census data set downloaded Jan, 2018.


COSMIC gene census list. Total genes 719, COSMIC genes mapped to antineoplastic drug targets 46
ncbi_gene_id Gene Symbol Tumour Types(Somatic) drugs
1019 CDK4 abemaciclib; palbociclib; ribociclib
1021 CDK6 ALL abemaciclib; palbociclib; ribociclib
2066 ERBB4 melanoma, gastric, NSCLC afatinib; neratinib
5979 RET medullary thyroid, papillary thyroid, pheochromocytoma, NSCLC, Spitzoid tumour alectinib; lenvatinib; cabozantinib; sunitinib; sorafenib; vandetanib
5914 RARA APL alitretinoin; tretinoin
3791 KDR NSCLC, angiosarcoma apatinib; lenvatinib; cabozantinib; sunitinib; nintedanib; regorafenib; ramucirumab; pazopanib; sorafenib; vandetanib; axitinib; tivozanib
29126 CD274 PMBL, Hodgkin lymphoma atezolizumab; avelumab; durvalumab
4233 MET papillary renal, head-neck squamous cell cabozantinib; crizotinib
2322 FLT3 AML, ALL cabozantinib; sunitinib; sorafenib; midostaurin
238 ALK ALCL, NSCLC, neuroblastoma, inflammatory myofibroblastic tumour, Spitzoid tumour ceritinib; alectinib; crizotinib; brigatinib
5604 MAP2K1 NSCLC, melanoma, colorectal cobimetinib; trametinib
5290 PIK3CA colorectal, gastric, glioblastoma, breast copanlisib
5424 POLD1 CRC cytarabine; gemcitabine
5426 POLE colorectal carcinoma, endometrioid carcinoma, stomach carcinoma, skin cancer cytarabine; gemcitabine
673 BRAF melanoma, colorectal, papillary thyroid, borderline ovarian, NSCLC, cholangiocarcinoma, pilocytic astrocytoma, Spitzoid tumour, pancreas acinar carcinoma, melanocytic nevus, prostate, gastric dabrafenib; sorafenib; vemurafenib; regorafenib
6714 SRC colorectal cancer, endometrial carcinoma dasatinib; bosutinib
1788 DNMT3A AML decitabine; azacitidine
3418 IDH2 glioblastoma enasidenib
367 AR prostate flutamide; nilutamide; cyproterone acetate; bicalutamide; enzalutamide; apalutamide
695 BTK CLL, mantle cell lymphoma, WM ibrutinib; acalabrutinib
1956 EGFR glioma, NSCLC icotinib; olmutinib; necitumumab; erlotinib; gefitinib; lapatinib; cetuximab; panitumumab; vandetanib; afatinib; osimertinib; neratinib
7150 TOP1 AML* irinotecan; belotecan
3815 KIT GIST, AML, TGCT, mastocytosis, mucosal melanoma lenvatinib; cabozantinib; sunitinib; pazopanib; sorafenib; dasatinib; imatinib
2260 FGFR1 MPN, NHL, salivary adenoma lenvatinib; nintedanib; pazopanib
2324 FLT4 soft tissue sarcoma lenvatinib; sunitinib; nintedanib; pazopanib; sorafenib; axitinib; tivozanib
1233 CCR4 adult T-cell leukaemia/lymphoma mogamulizumab
2263 FGFR2 gastric, NSCLC, endometrial nintedanib
2264 FGFR4 rhabdomyosarcoma nintedanib
5156 PDGFRA GIST, idiopathic hypereosinophilic syndrome, paediatric glioblastoma olaratumab; lenvatinib; nintedanib; sunitinib; pazopanib
3702 ITK peripheral T-cell lymphoma pazopanib
3932 LCK T-ALL pazopanib; dasatinib
2261 FGFR3 bladder, MM, T-cell lymphoma pazopanib; nintedanib
7852 CXCR4 WM plerixafor
613 BCR CML, ALL, AML ponatinib
25 ABL1 CML, ALL, T-ALL radotinib; ponatinib; dasatinib; imatinib; nilotinib; bosutinib
2475 MTOR endometrial carcinoma, head and neck, clear cell renal cell carcinoma, anaplastic thyroid cancer, urothelial cell carcinoma, central nervous system tumours, testicular germ cell tumours and other tumour types ridaforolimus
3716 JAK1 ALL ruxolitinib
3717 JAK2 ALL, AML, MPN, CML ruxolitinib
5894 RAF1 pilocytic astrocytoma, prostate sorafenib
1436 CSF1R MDS, CML, AML, hemangioblastoma, CCRCC sunitinib; pazopanib
5159 PDGFRB MPN, AML, CMML, CML sunitinib; pazopanib; sorafenib; dasatinib; imatinib; nintedanib
2099 ESR1 breast toremifene; fulvestrant; tamoxifen; fosfestrol
5605 MAP2K2 NSCLC, melanoma trametinib
2064 ERBB2 breast, ovarian, other tumour types, NSCLC, gastric trastuzumab emtansine; lapatinib; pertuzumab; afatinib; trastuzumab; neratinib
596 BCL2 NHL, CLL venetoclax
6608 SMO skin basal cell vismodegib; sonidegib
29974 A1CF melanoma -
10006 ABI1 AML -
27 ABL2 AML -
57007 ACKR3 lipoma -
2181 ACSL3 prostate -
23305 ACSL6 AML, AEL -
90 ACVR1 DIPG -
92 ACVR2A large intestine carcinoma, stomach carcinoma, pancreatic carcinoma, biliary tract, oesophagus -
4299 AFF1 AL -
3899 AFF3 ALL, T-ALL -
27125 AFF4 ALL -
10142 AKAP9 papillary thyroid -
207 AKT1 breast, colorectal, ovarian, NSCLC -
208 AKT2 ovarian, pancreatic -
10000 AKT3 GBM -
217 ALDH2 leiomyoma -
139285 AMER1 Wilms tumour -
286 ANK1 CCRCC -
324 APC colorectal, pancreatic, desmoid, hepatoblastoma, glioma, other CNS -
9582 APOBEC3B -
369 ARAF cholangiocarcinoma, lung adenocarcinoma, Langerhans cell histiocytosis -
23092 ARHGAP26 AML, MDS -
394 ARHGAP5 colon cancer, glioma -
9639 ARHGEF10 colon cancer -
55160 ARHGEF10L lymphoma -
23365 ARHGEF12 AML -
8289 ARID1A clear cell ovarian carcinoma, RCC, breast -
57492 ARID1B breast, hepatocellular carcinoma -
196528 ARID2 hepatocellular carcinoma -
405 ARNT AML -
79058 ASPSCR1 alveolar soft part sarcoma -
171023 ASXL1 MDS, CMML -
55252 ASXL2 melanoma, CCRCC, AML -
466 ATF1 malignant melanoma of soft parts, angiomatoid fibrous histiocytoma -
471 ATIC ALCL -
472 ATM T-PLL -
476 ATP1A1 adrenal aldosterone producing adenoma -
492 ATP2B3 adrenal aldosterone producing adenoma -
545 ATR endometrial, gastric, epithelial ovarian, myeloma -
546 ATRX pancreatic neuroendocrine tumours, paediatric GBM -
8312 AXIN1 colorectal, endometrial, prostate, hepatocellular carcinoma, hepatoblastoma, sporadic medulloblastoma -
8313 AXIN2 colorectal carcinoma, stomach carcinoma, hepatocellular carcinoma -
567 B2M DLBCL, melanoma, colorectal adenocarcinoma -
8314 BAP1 uveal melanoma, breast, NSCLC, RCC -
580 BARD1 breast cancer -
581 BAX colorectal cancer -
11177 BAZ1A uterine carcinosarcoma, colon cancer -
8915 BCL10 MALT -
53335 BCL11A B-CLL -
64919 BCL11B T-ALL -
83596 BCL2L12 melanoma, SCC -
602 BCL3 CLL -
604 BCL6 NHL, CLL -
605 BCL7A BNHL -
607 BCL9 B-ALL -
283149 BCL9L colorectal cancer, endometrial carcinoma, gastric cancer -
9774 BCLAF1 melanoma, SCC -
54880 BCOR retinoblastoma, AML, APL (translocation) -
63035 BCORL1 AML, HNSCC -
330 BIRC3 CLL, MALT, MCL, MM -
57448 BIRC6 melanoma, gastric adenocarcinoma, lung adenocarcinoma -
641 BLM -
653 BMP5 melanoma -
657 BMPR1A -
672 BRCA1 ovarian -
675 BRCA2 breast, ovarian, pancreatic -
8019 BRD3 lethal midline carcinoma of young people -
23476 BRD4 lethal midline carcinoma of young people -
83990 BRIP1 -
694 BTG1 B-CLL -
701 BUB1B -
145788 C15orf65 PMBL, Hodgkin lymphoma -
80304 C2orf44 colorectal -
776 CACNA1D adrenal aldosterone producing adenoma -
811 CALR MPN, MDS -
23261 CAMTA1 epithelioid haemangioendothelioma -
124583 CANT1 prostate -
84433 CARD11 DLBCL -
833 CARS ALCL -
57082 CASC5 AML -
836 CASP3 ovarian cancer -
841 CASP8 hepatocellular, oral squamous cell, breast -
842 CASP9 glioma -
863 CBFA2T3 AML -
865 CBFB AML -
867 CBL AML, JMML, MDS -
868 CBLB AML -
23624 CBLC AML -
8030 CCDC6 papillary thyroid, CML, NSCLC -
57820 CCNB1IP1 leiomyoma -
892 CCNC T-ALL -
595 CCND1 CLL, B-ALL, breast -
894 CCND2 NHL,CLL -
896 CCND3 MM -
898 CCNE1 serous ovarian -
1236 CCR7 adult T-cell leukaemia/lymphoma -
30835 CD209 prostate carcinoma -
940 CD28 T-cell lymphoma -
972 CD74 NSCLC -
973 CD79A DLBCL, WM -
974 CD79B DLBCL, WM -
79577 CDC73 parathyroid adenoma -
999 CDH1 lobular breast, gastric -
1008 CDH10 melanoma -
1009 CDH11 aneurysmal bone cyst -
1015 CDH17 melanoma -
51755 CDK12 serous ovarian -
1026 CDKN1A bladder cancer -
1027 CDKN1B breast, small intestine neuroendocrine tumours -
1029 CDKN2A melanoma, multiple other tumour types -
1031 CDKN2C glioma, MM -
1045 CDX2 AML -
1050 CEBPA AML, MDS -
84902 CEP89 Spitzoid tumour -
79145 CHCHD7 salivary adenoma -
1106 CHD2 melanoma, large intestine, CLL, monoclonal B lymphocytosis -
1108 CHD4 uterine serous carcinoma -
11200 CHEK2 -
26511 CHIC2 AML -
50515 CHST11 B-CLL -
23152 CIC oligodendroglioma, soft tissue sarcoma -
4261 CIITA PMBL, Hodgkin lymphoma -
6249 CLIP1 Spitzoid tumour -
10978 CLP1 AML -
1213 CLTC ALCL, renal -
8218 CLTCL1 ALCL -
168975 CNBD1 gastric cancer, colon cancer -
7555 CNBP aneurysmal bone cyst -
4849 CNOT3 T-ALL -
26047 CNTNAP2 glioma, melanoma -
11064 CNTRL MPN, NHL -
1277 COL1A1 DFSP, aneurysmal bone cyst -
1280 COL2A1 chondrosarcoma, enchondroma -
1281 COL3A1 lipoblastoma -
1345 COX6C uterine leiomyoma -
22849 CPEB3 lung cancer -
1385 CREB1 clear cell sarcoma, angiomatoid fibrous histiocytoma -
90993 CREB3L1 myxofibrosarcoma -
64764 CREB3L2 fibromyxoid sarcoma -
1387 CREBBP ALL, AML, DLBCL, B-NHL -
64109 CRLF2 B-ALL, Downs associated ALL -
51340 CRNKL1 base cell carcinoma -
23373 CRTC1 salivary gland mucoepidermoid -
64784 CRTC3 salivary gland mucoepidermoid -
1441 CSF3R aCML, CNL, leukaemia lymphoma and MDS associated with severe congenital neutropenia, CMML, de novo AML, MDS -
114788 CSMD3 ovarian cancer, oral SCC, lung cancer -
10664 CTCF endometrial, breast, head and neck cancer -
1496 CTNNA2 gastric cancer -
1499 CTNNB1 colorectal, ovarian, hepatoblastoma, pleomorphic salivary gland adenoma, other tumour types -
1500 CTNND1 large intestine carcinoma -
1501 CTNND2 prostae adenocarcinoma, GIST -
8452 CUL3 lung cancer -
1523 CUX1 endometrial, melanoma, colorectal, AML, MDS, other tumour types -
1540 CYLD cylindroma -
1558 CYP2C8 melanoma -
57105 CYSLTR2 uveal melanoma -
1616 DAXX pancreatic neuroendocrine tumour, paediatric glioblastoma -
340578 DCAF12L2 CRC -
1630 DCC CRC, melanoma, SCC -
1639 DCTN1 inflammatory myofibroblastic tumour, Spitzoid tumour -
1643 DDB2 -
1649 DDIT3 liposarcoma -
4921 DDR2 squamous cell carcinoma, NSCLC -
1662 DDX10 AML* -
1654 DDX3X CLL, medulloblastoma -
1655 DDX5 prostate -
1656 DDX6 B-NHL -
7913 DEK AML -
54487 DGCR8 Wilms tumour -
23405 DICER1 sex cord-stromal tumour, TGCT, embryonal rhabdomyosarcoma, pleuropulmonary blastoma, pituitary blastoma, Wilms tumour, thyroid cancer, other tumour types -
3337 DNAJB1 fibrolamellar hepatocellular carcinoma -
1785 DNM2 T-ALL -
29102 DROSHA Wilms tumour, NSCLC, bladder carcinoma -
22947 DUX4L1 soft tissue sarcoma -
1879 EBF1 lipoma -
345930 ECT2L ETP ALL -
8726 EED malignant peripheral nerve sheath tumours, MDS and related, lung adenocarcinoma -
1964 EIF1AX uveal melanoma, thyroid cancer (PDTC and ATC), low grade serous ovarian cancer -
3646 EIF3E colorectal -
1974 EIF4A2 NHL -
1999 ELF3 pancreatic cancer -
2000 ELF4 AML -
2005 ELK4 prostate -
8178 ELL AL -
2006 ELN B-ALL -
27436 EML4 NSCLC -
2033 EP300 colorectal, breast, pancreatic, AML, ALL, DLBCL -
2034 EPAS1 paraganglioma, pheochromocytoma, central nervous system hemangioblastomas -
2042 EPHA3 lung cancer, CRC, melanoma -
2045 EPHA7 CRC, melanoma -
2060 EPS15 ALL -
2065 ERBB3 colon, gastric, head and neck, bladder, skin -
23085 ERC1 papillary thyroid, Spitzoid tumour -
2068 ERCC2 -
2071 ERCC3 -
2072 ERCC4 -
2073 ERCC5 -
2078 ERG Ewing sarcoma, prostate, AML -
55500 ETNK1 aCML, CMML, SM-AHD, HES -
2115 ETV1 Ewing sarcoma, prostate -
2118 ETV4 Ewing sarcoma, prostate carcinoma -
2119 ETV5 prostate -
2120 ETV6 congenital fibrosarcoma, multiple different leukaemia and lymphoma tumour types including ALL, secretory breast, MDS -
2130 EWSR1 Ewing sarcoma, desmoplastic small round cell tumour , ALL, clear cell sarcoma, sarcoma, myoepithelioma, mesothelioma -
2131 EXT1 -
2132 EXT2 -
2146 EZH2 DLBCL -
7430 EZR NSCLC -
9715 FAM131B pilocytic astrocytoma -
51059 FAM135B SCLC -
54855 FAM46C MM -
442444 FAM47C melanoma, clear cell sarcoma of soft parts, SCLC -
2175 FANCA -
2176 FANCC -
2177 FANCD2 -
2178 FANCE -
2188 FANCF -
2189 FANCG -
355 FAS TGCT, nasal NK/T lymphoma, skin squamous cell carcinoma-burn scar related -
2195 FAT1 oral squamous cell, chemorefractory CLL, head and neck, pancreatic acinar cell carcinoma -
120114 FAT3 SCC, colon adenocarcinoma, gastric adenocarcinoma -
79633 FAT4 lymphoma, pancreatic, head and neck, melanoma, hepatocellular carcinoma -
2199 FBLN2 breast cancer, colorectal adenocarcinoma -
80204 FBXO11 DLBCL -
55294 FBXW7 colorectal, endometrial, T-ALL -
2213 FCGR2B ALL -
83417 FCRL4 B-NHL -
2237 FEN1 -
2242 FES HNSCC, ovarian carcinoma -
54738 FEV Ewing sarcoma -
11116 FGFR1OP MPN, NHL -
2271 FH -
2272 FHIT pleomorphic salivary gland adenoma -
81608 FIP1L1 idiopathic hypereosinophilic syndrome -
11328 FKBP9 glioma -
201163 FLCN -
2313 FLI1 Ewing sarcoma -
2316 FLNA phyllodes tumour of the breast -
23048 FNBP1 AML -
3169 FOXA1 breast, prostate -
668 FOXL2 granulosa-cell tumour of the ovary -
2308 FOXO1 alveolar rhabdomyosarcoma -
2309 FOXO3 AL -
4303 FOXO4 AL, soft tissue sarcoma -
27086 FOXP1 ALL -
283150 FOXR1 neuroblastoma -
10272 FSTL3 B-CLL -
8880 FUBP1 oligodendroglioma -
2521 FUS liposarcoma, AML, Ewing sarcoma, angiomatoid fibrous histiocytoma, fibromyxoid sarcoma -
8522 GAS7 AML* -
2623 GATA1 megakaryoblastic leukaemia of Downs syndrome -
2624 GATA2 AML (CML blast transformation) -
2625 GATA3 breast -
2735 GLI1 CRC, oesophagus cancer -
8833 GMPS AML -
2767 GNA11 uveal melanoma, primary central nervous system melanocytic neoplasms -
2776 GNAQ uveal melanoma, primary central nervous system melanocytic neoplasms -
2778 GNAS pituitary adenoma, pancreatic intraductal papillary mucinous neoplasm, fibrous dysplasia -
9950 GOLGA5 papillary thyroid, Spitzoid tumour -
57120 GOPC glioblastoma, cholangiocarcinoma, borderline ovarian -
2719 GPC3 -
2262 GPC5 lung adenocarcinoma -
10243 GPHN AL -
2903 GRIN2A melanoma, colorectal carcinoma, gastric carcinoma, lung carcinoma -
2913 GRM3 melanoma, oral SCC -
3020 H3F3A glioma -
3021 H3F3B chondroblastoma -
9709 HERPUD1 prostate -
23462 HEY1 mesenchymal chondrosarcoma -
3091 HIF1A endometrioid carcinoma, glioblastoma, colorectal, renal, lung, pancreatic -
3092 HIP1 CMML, NSCLC -
8358 HIST1H3B glioma -
8294 HIST1H4I NHL -
3105 HLA-A Spitzoid tumour -
3131 HLF ALL -
3159 HMGA1 microfollicular thyroid adenoma, various benign mesenchymal tumours -
8091 HMGA2 lipoma, leiomyoma, pleomorphic salivary gland adenoma -
283651 HMGN2P46 prostate -
6927 HNF1A hepatic adenoma, hepatocellular -
3181 HNRNPA2B1 prostate -
84376 HOOK3 papillary thyroid -
3207 HOXA11 CML -
3209 HOXA13 AML -
3205 HOXA9 AML* -
3227 HOXC11 AML -
3229 HOXC13 AML -
3237 HOXD11 AML -
3239 HOXD13 AML* -
3265 HRAS infrequent sarcomas, rare other tumour types -
3320 HSP90AA1 NHL -
3326 HSP90AB1 NHL -
3399 ID3 Burkitt lymphoma -
3417 IDH1 glioblastoma -
10644 IGF2BP2 lymphoma -
3492 IGH MM, Burkitt lymphoma, NHL, CLL, B-ALL, MALT, MLCLS -
50802 IGK Burkitt lymphoma, B-NHL -
3535 IGL Burkitt lymphoma -
3551 IKBKB SMZL -
10320 IKZF1 ALL, DLBCL -
3558 IL2 intestinal T-cell lymphoma -
50615 IL21R NHL -
3572 IL6ST hepatocellular carcinoma -
3575 IL7R ALL, ETP ALL -
3662 IRF4 MM -
8471 IRS4 glioma, rhabdomyosarcoma, melanoma, breast cancer, T-ALL -
91464 ISX melanoma -
3685 ITGAV large intestine carcinoma -
3718 JAK3 acute megakaryocytic leukaemia, ETP ALL -
221895 JAZF1 endometrial stromal tumour -
3725 JUN sarcoma -
7994 KAT6A AML -
23522 KAT6B AML, leiomyoma -
11143 KAT7 CCRCC -
3762 KCNJ5 adrenal adenoma -
5927 KDM5A AML -
8242 KDM5C clear cell renal carcinoma -
7403 KDM6A renal cell carcinoma, bladder carcinoma, oesophageal SCC, MM, medulloblastoma, T-ALL, other tumour types -
2531 KDSR B-NHL -
9817 KEAP1 NSCLC, breast carcinoma -
57670 KIAA1549 pilocytic astrocytoma -
57698 KIAA1598 Spitzoid tumour -
3799 KIF5B NSCLC, Spitzoid tumour -
9314 KLF4 meningioma -
1316 KLF6 prostate, glioma -
3817 KLK2 prostate -
4297 KMT2A AML, ALL -
58508 KMT2C medulloblastoma -
8085 KMT2D medulloblastoma, renal -
90417 KNSTRN SCC -
3845 KRAS pancreatic, colorectal, lung, thyroid, AML, other tumour types -
3895 KTN1 papillary thyroid -
23185 LARP4B CRC, glioma -
3927 LASP1 AML -
3936 LCP1 NHL -
51176 LEF1 B-ALL, T-ALL, eyelid sebaceous carcinoma, AML, lymphomas -
23484 LEPROTL1 lung cancer, colon cancer -
10186 LHFP lipoma -
3977 LIFR salivary adenoma -
4000 LMNA Spitzoid tumour -
4004 LMO1 T-ALL, neuroblastoma -
4005 LMO2 T-ALL -
4026 LPP lipoma, leukaemia -
121227 LRIG3 NSCLC -
53353 LRP1B CLL, ovarian cancer, oesophageal squamous cell carcinoma, urothelial cancer -
26065 LSM14A Spitzoid tumour -
4066 LYL1 T-ALL -
8216 LZTR1 glioblastoma -
4094 MAF MM -
9935 MAFB MM -
378938 MALAT1 renal cell carcinoma (childhood epithelioid), lung -
10892 MALT1 MALT -
84441 MAML2 salivary gland mucoepidermoid -
6416 MAP2K4 pancreatic, breast, colorectal -
4214 MAP3K1 luminal A breast -
9175 MAP3K13 breast -
5594 MAPK1 CLL, ovarian mixed germ cell tumour, cervical carcinoma -
4149 MAX pheochromocytoma, endometrioid carcinoma, colon carcinoma -
151963 MB21D2 lung cancer -
4193 MDM2 sarcoma, glioma, colorectal, other tumour types -
4194 MDM4 glioblastoma, bladder, retinoblastoma -
259283 MDS2 MDS -
2122 MECOM AML, CML, MDS -
9968 MED12 uterine leiomyoma, fibroadenoma, phyllodes tumour -
4221 MEN1 parathyroid tumours, pancreatic neuroendocrine tumour -
4255 MGMT glioma -
4286 MITF melanoma -
57591 MKL1 acute megakaryocytic leukaemia -
4291 MLF1 AML -
4292 MLH1 colorectal, endometrial, ovarian, CNS tumours -
4298 MLLT1 AL -
8028 MLLT10 AL -
10962 MLLT11 ALL -
4300 MLLT3 ALL -
4301 MLLT4 AL -
4302 MLLT6 AL -
4330 MN1 AML, meningioma -
3110 MNX1 AML -
4352 MPL MPN -
4436 MSH2 colorectal, endometrial, ovarian -
2956 MSH6 colorectal -
124540 MSI2 CML -
4478 MSN ALCL -
4515 MTCP1 T cell prolymphocytic leukaemia -
4582 MUC1 B-NHL -
94025 MUC16 HNSCC, melanoma -
4585 MUC4 HNSCC -
4595 MUTYH -
4602 MYB adenoid cystic carcinoma -
4609 MYC Burkitt lymphoma, amplified in other cancers, B-CLL -
4610 MYCL small cell lung carcinoma -
4613 MYCN neuroblastoma -
4615 MYD88 ABC-DLBCL -
4629 MYH11 AML -
4627 MYH9 ALCL -
4644 MYO5A Spitzoid tumour -
4654 MYOD1 embryonal rhabdomyosarcoma -
55728 N4BP2 lung cancer -
4665 NAB2 solitary fibrous tumour, meningeal haemangiopericytoma -
4666 NACA NHL -
26960 NBEA large intestine carcinoma, multiple myeloma -
4683 NBN -
51517 NCKIPSD ALL -
8648 NCOA1 alveolar rhabdomyosarcoma -
10499 NCOA2 AML, chondrosarcoma, rhabdomyosarcoma -
8031 NCOA4 papillary thyroid -
9611 NCOR1 breast -
9612 NCOR2 prostate -
10397 NDRG1 prostate -
4763 NF1 neurofibroma, glioma -
4771 NF2 meningioma, acoustic neuroma, renal -
4773 NFATC2 Ewing sarcoma -
4780 NFE2L2 NSCLC, HNSCC -
4781 NFIB adenoid cystic carcinoma, lipoma -
4791 NFKB2 B-NHL -
4794 NFKBIE CLL, desmoplastic melanoma -
51199 NIN MPN -
7080 NKX2-1 NSCLC -
4841 NONO papillary renal -
4851 NOTCH1 T-ALL, breast, bladder, skin SCC, lung SCC, head and neck SCC -
4853 NOTCH2 marginal zone lymphoma, DLBCL, bladder -
4869 NPM1 NHL, APL, AML -
8013 NR4A3 extraskeletal myxoid chondrosarcoma -
4893 NRAS melanoma, MM, AML, thyroid -
3084 NRG1 NSCLC -
64324 NSD1 AML -
22978 NT5C2 relapse ALL -
4913 NTHL1 CRC -
4914 NTRK1 papillary thyroid, Spitzoid tumour -
4916 NTRK3 congenital fibrosarcoma, secretory breast -
4926 NUMA1 APL -
8021 NUP214 AML, T-ALL -
4928 NUP98 AML -
256646 NUTM1 lethal midline carcinoma -
728118 NUTM2A endometrial stromal sarcoma -
729262 NUTM2B endometrial stromal sarcoma -
10215 OLIG2 T-ALL -
4958 OMD aneurysmal bone cyst -
286530 P2RY8 B-ALL, Down syndrome associated ALL -
26986 PABPC1 HNSCC, biliary tract carcinoma -
5049 PAFAH1B2 MLCLS -
79728 PALB2 -
5077 PAX3 alveolar rhabdomyosarcoma -
5079 PAX5 NHL, ALL, B-ALL -
5081 PAX7 alveolar rhabdomyosarcoma -
7849 PAX8 follicular thyroid -
55193 PBRM1 clear cell renal carcinoma, breast -
5087 PBX1 pre B-ALL, myoepithelioma -
5093 PCBP1 CRC -
5108 PCM1 papillary thyroid, CML, MPN -
80380 PDCD1LG2 PMBL, Hodgkin lymphoma -
9659 PDE4DIP MPN -
5155 PDGFB DFSP -
5187 PER1 AML, CMML -
84295 PHF6 ETP ALL -
8929 PHOX2B neuroblastoma -
8301 PICALM T-ALL, AML -
5291 PIK3CB SCC, NSCLC -
5295 PIK3R1 glioblastoma, ovarian, colorectal -
5292 PIM1 NHL -
5324 PLAG1 salivary adenoma, lipoblastoma -
5335 PLCG1 angiosarcoma -
5371 PML APL, ALL -
5378 PMS1 -
5395 PMS2 -
5428 POLG CRC -
10721 POLQ oral SCC -
25913 POT1 CLL -
5450 POU2AF1 NHL -
5460 POU5F1 sarcoma -
5468 PPARG follicular thyroid -
8496 PPFIBP1 Spitzoid tumour, inflammatory myofibroblastic tumour -
8493 PPM1D glioma, ovarian cancer, breast cancer -
5518 PPP2R1A clear cell ovarian carcinoma -
5537 PPP6C melanoma -
5546 PRCC papillary renal -
639 PRDM1 DLBCL -
63976 PRDM16 MDS, AML -
7799 PRDM2 glioma, colon adenocarcinoma, gastric carcinoma, ovarian carcinoma, HNSCC -
80243 PREX2 melanoma, pancreatic ductal adenocarcinoma -
5551 PRF1 -
5566 PRKACA fibrolamellar hepatocellular carcinoma, cortisol secreting adrenal adenoma -
5573 PRKAR1A papillary thyroid -
5579 PRKCB adult T-cell lymphoma-leukaemia -
25766 PRPF40B melanoma, colon carcinoma, MDS -
5396 PRRX1 AML -
11168 PSIP1 AML -
5727 PTCH1 skin basal cell, medulloblastoma -
5728 PTEN glioma, prostate, endometrial -
5753 PTK6 renal, gastric, head and neck, ovarian, others -
5781 PTPN11 JMML, AML, MDS -
5783 PTPN13 lung, NSCLC, gastric, peritoneal carcinomatosis -
5777 PTPN6 DLBCL -
5787 PTPRB angiosarcoma -
5788 PTPRC T-ALL -
5789 PTPRD lung cancer, kidney cancer, HNSCC, glioblastoma -
5796 PTPRK colorectal -
11122 PTPRT HNSCC, colorectal cancer, gastric cancer, lung cancer, melanoma -
114825 PWWP2A Spitzoid tumour -
9444 QKI angiocentric glioma, colorectal cancer -
9135 RABEP1 CMML -
5879 RAC1 melanoma, carcinoma -
5884 RAD17 lymphoma, colon cancer -
5885 RAD21 AML, endometrium, colorectal, lung -
5890 RAD51B lipoma, uterine leiomyoma -
5900 RALGDS PMBL, Hodgkin lymphoma, -
5903 RANBP2 inflammatory myofibroblastic tumour -
5910 RAP1GDS1 T-ALL -
5925 RB1 retinoblastoma, sarcoma, breast, small cell lung carcinoma -
8241 RBM10 lung adenocarcinoma -
64783 RBM15 acute megakaryocytic leukaemia -
9401 RECQL4 -
5966 REL Hodgkin lymphoma -
55159 RFWD3 lung cancer -
653489 RGPD3 endometrioid adenocarcinoma -
6000 RGS7 melanoma -
387 RHOA diffuse gastric, T cell lymphomas, paediatric Burkitt lymphoma -
399 RHOH NHL -
116028 RMI2 PMBL, Hodgkin lymphoma -
57674 RNF213 ALCL -
54894 RNF43 cholangiocarcinoma, ovary, pancreas -
6092 ROBO2 colorectal adenocarcinoma, melanoma -
6098 ROS1 glioblastoma, NSCLC, Spitzoid tumour, cholangiocarcinoma, borderline ovarian -
6134 RPL10 T-ALL -
6146 RPL22 AML, CML -
6125 RPL5 T-ALL -
6184 RPN1 AML -
340419 RSPO2 colorectal -
84870 RSPO3 colorectal -
92017 RUNDC2A PMBL, Hodgkin lymphoma -
861 RUNX1 AML, pre B-ALL, T-ALL -
862 RUNX1T1 AML -
6278 S100A7 melanoma, T-cell lymphoma -
57167 SALL4 colorectal cancer, breast cancer, prostate cancer, glioblastoma, melanoma -
51119 SBDS -
6385 SDC4 NSCLC -
6389 SDHA GIST, paraganglioma -
54949 SDHAF2 -
6390 SDHB -
6391 SDHC -
6392 SDHD -
5413 SEPT5 AML -
23157 SEPT6 AML -
10801 SEPT9 AML* -
6418 SET T-ALL -
26040 SETBP1 aCML, sAML, MDS/MPN-U, CMML, JMML -
23067 SETD1B CRC, endometrium -
29072 SETD2 clear cell renal carcinoma -
23451 SF3B1 myelodysplastic syndrome -
6421 SFPQ papillary renal -
6424 SFRP4 colorectal cancer, melanoma, SCC, gastric cancer, oesophageal SCC -
6446 SGK1 Nodular lymphocyte predominant Hodgkin lymphoma -
10019 SH2B3 MPN, sAML, erythrocytosis, B-ALL -
6455 SH3GL1 AL -
140885 SIRPA HNSCC, colorectal cancer, Lung SCC -
6495 SIX1 Wilms tumour -
10736 SIX2 Wilms tumour -
6497 SKI melanoma -
10568 SLC34A2 NSCLC -
85414 SLC45A3 prostate -
4087 SMAD2 colorectal carcinoma, hepatocellular carcinoma -
4088 SMAD3 colorectal carcinoma, oral squamous cell carcinoma -
4089 SMAD4 colorectal, pancreatic, small intestine -
6597 SMARCA4 NSCLC, SCCOHT -
6598 SMARCB1 malignant rhabdoid -
6602 SMARCD1 breast -
6605 SMARCE1 -
8243 SMC1A AML -
27044 SND1 pancreas acinar carcinoma -
8651 SOCS1 Hodgkin lymphoma, PMBL -
6657 SOX2 NSCLC, oesophageal squamous carcinoma -
11166 SOX21 multiple myeloma -
92521 SPECC1 JMML -
23013 SPEN SMZL, adenoid cystic carcinoma, DLBCL -
8405 SPOP prostate, endometrial -
9901 SRGAP3 pilocytic astrocytoma -
6427 SRSF2 MDS, CLL -
6428 SRSF3 follicular lymphoma -
6760 SS18 synovial sarcoma -
26039 SS18L1 synovial sarcoma -
6756 SSX1 synovial sarcoma -
6757 SSX2 synovial sarcoma -
6759 SSX4 synovial sarcoma -
10274 STAG1 colorectal cancer, AML -
10735 STAG2 bladder carcinoma, glioblastoma, melanoma, Ewing's sarcoma, myeloid neoplasms -
6774 STAT3 T-cell large granular lymphocytic leukaemia -
6777 STAT5B large granular lymphocytic leukaemia, skin basal cell, APL -
6778 STAT6 solitary fibrous tumour, meningeal haemangiopericytoma -
6491 STIL T-ALL -
6794 STK11 NSCLC, pancreatic -
6801 STRN anaplastic thyroid, papillary thyroid, lung -
51684 SUFU medulloblastoma -
23512 SUZ12 endometrial stromal tumour -
6850 SYK MDS, peripheral T-cell lymphoma -
8148 TAF15 extraskeletal myxoid chondrosarcoma, ALL -
6886 TAL1 lymphoblastic leukaemia/biphasic -
6887 TAL2 T-ALL -
79718 TBL1XR1 splenic marginal zone lymphoma, primary central nervous system lymphoma, colorectal carcinoma, gallbladder carcinoma -
6926 TBX3 breast, large intestine, skin -
6917 TCEA1 salivary adenoma -
6938 TCF12 extraskeletal myxoid chondrosarcoma -
6929 TCF3 pre B-ALL -
6934 TCF7L2 colorectal -
8115 TCL1A T-CLL -
7006 TEC myxoid chondrosarcoma -
7015 TERT melanoma, glioblastoma, hepatocellular carcinoma, bladder, skin basal cell, skin squamous cell, mesothelioma, medulloblastoma, other tumour types -
80312 TET1 AML -
54790 TET2 MDS -
7030 TFE3 papillary renal, alveolar soft part sarcoma, renal -
7942 TFEB renal cell carcinoma (childhood epithelioid) -
10342 TFG papillary thyroid, ALCL, NSCLC, extraskeletal myxoid chondrosarcoma -
29844 TFPT pre-B ALL -
7037 TFRC NHL -
7048 TGFBR2 head and neck, colorectal -
9967 THRAP3 aneurysmal bone cyst -
3195 TLX1 T-ALL -
30012 TLX3 T-ALL -
55654 TMEM127 -
7113 TMPRSS2 prostate -
3371 TNC SCC, melanoma -
7128 TNFAIP3 marginal zone B-cell lymphomas, Hodgkin lymphoma, PMBL -
8764 TNFRSF14 follicular lymphoma -
608 TNFRSF17 intestinal T-cell lymphoma -
7157 TP53 breast, colorectal, lung, sarcoma, adrenocortical, glioma, Spitzoid tumour, multiple other tumour types -
8626 TP63 HNSCC, DLBCL -
7170 TPM3 papillary thyroid, ALCL, NSCLC, Spitzoid tumour -
7171 TPM4 ALCL -
7175 TPR papillary thyroid, NSCLC -
6955 TRA T-ALL -
84231 TRAF7 meningioma -
6957 TRB T-ALL -
6964 TRD T-cell leukaemia -
8805 TRIM24 APL -
5987 TRIM27 papillary thyroid -
51592 TRIM33 papillary thyroid -
9321 TRIP11 AML -
8295 TRRAP melanoma -
7248 TSC1 renal cell carcinoma, bladder carcinoma -
7249 TSC2 pulmonary lymphangioleiomyomatosis (LAM), renal angiomyolipoma, HNSCC -
7253 TSHR toxic thyroid adenoma -
7307 U2AF1 CLL, MDS -
51366 UBR5 mantle cell lymphoma, gastric, colorectal -
84101 USP44 lung cancer, colon cancer -
9098 USP6 aneurysmal bone cyst -
9101 USP8 corticotroph adenoma -
7409 VAV1 T-cell lymphoma -
7428 VHL renal, haemangioma, pheochromocytoma -
143187 VTI1A colorectal -
7454 WAS -
7468 WHSC1 MM -
54904 WHSC1L1 AML -
11197 WIF1 pleomorphic salivary gland adenoma -
65268 WNK2 gastric cancer -
7486 WRN -
7490 WT1 Wilms tumour, desmoplastic small round cell tumour -
25937 WWTR1 epithelioid haemangioendothelioma -
7507 XPA -
7508 XPC -
7514 XPO1 CLL -
7531 YWHAE endometrial stromal sarcoma -
7704 ZBTB16 APL -
55596 ZCCHC8 Spitzoid tumour -
6935 ZEB1 CCRCC, melanoma -
463 ZFHX3 endometrial, gastric, prostate -
9203 ZMYM3 CRC, breast cancer -
7750 ZNF198 MPN, NHL -
23598 ZNF278 Ewing sarcoma -
55422 ZNF331 follicular thyroid adenoma -
171017 ZNF384 ALL -
353088 ZNF429 GBM -
90827 ZNF479 lung cancer, bladder carcinoma, prostate carcinoma -
25925 ZNF521 ALL -
84133 ZNRF3 colorectal cancer, adrenocortical carcinoma, gastric cancer -
8233 ZRSR2 MDS, CLL -

Antineoplastic drug targets only
ncbi_gene_id drugs symbol name
100 pentostatin ADA Adenosine deaminase
142 rucaparib; olaparib; niraparib PARP1 Poly [ADP-ribose] polymerase 1
915 blinatumomab CD3D T-cell surface glycoprotein CD3 delta chain
916 blinatumomab CD3E T-cell surface glycoprotein CD3 epsilon chain
917 blinatumomab CD3G T-cell surface glycoprotein CD3 gamma chain
930 blinatumomab CD19 B-lymphocyte antigen CD19
931 ofatumumab; rituximab; obinutuzumab; ibritumomab tiuxetan MS4A1 B-lymphocyte antigen CD20
933 inotuzumab ozogamicin CD22 B-cell receptor CD22
943 brentuximab vedotin TNFRSF8 Tumor necrosis factor receptor superfamily member 8
945 gemtuzumab ozogamicin CD33 Myeloid cell surface antigen CD33
952 daratumumab CD38 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
1493 ipilimumab CTLA4 Cytotoxic T-lymphocyte protein 4
1583 aminoglutethimide; mitotane CYP11A1 Cholesterol side-chain cleavage enzyme, mitochondrial
1584 mitotane CYP11B1 Cytochrome P450 11B1, mitochondrial
1586 abiraterone acetate CYP17A1 Steroid 17-alpha-hydroxylase/17,20 lyase
1588 testolactone; letrozole; exemestane; anastrozole; aminoglutethimide; fadrozole; vorozole CYP19A1 Aromatase
1719 methotrexate; pemetrexed; edatrexate; pralatrexate DHFR Dihydrofolate reductase
1786 decitabine; azacitidine DNMT1 DNA (cytosine-5)-methyltransferase 1
1806 gimeracil DPYD Dihydropyrimidine dehydrogenase [NADP(+)]
1890 tipiracil TYMP Thymidine phosphorylase
1969 dasatinib EPHA2 Ephrin type-A receptor 2
2100 fulvestrant; chlorotrianisene; fosfestrol ESR2 Estrogen receptor beta
2280 sirolimus; everolimus; temsirolimus FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A
2321 lenvatinib; nintedanib; sunitinib; pazopanib; sorafenib; axitinib; tivozanib FLT1 Vascular endothelial growth factor receptor 1
2534 dasatinib FYN Tyrosine-protein kinase Fyn
2798 triptorelin; leuprorelin; degarelix; buserelin; goserelin GNRHR Gonadotropin-releasing hormone receptor
2908 triamcinolone acetonide; prednisone; prednisolone; dexamethasone; mometasone furoate; alclometasone dipropionate NR3C1 Glucocorticoid receptor
2936 carmustine GSR Glutathione reductase, mitochondrial
3055 bosutinib HCK Tyrosine-protein kinase HCK
3065 chidamide; vorinostat; panobinostat; belinostat; romidepsin HDAC1 Histone deacetylase 1
3066 chidamide; vorinostat; panobinostat; belinostat; romidepsin HDAC2 Histone deacetylase 2
3269 histamine HRH1 Histamine H1 receptor
3559 aldesleukin; denileukin diftitox IL2RA Interleukin-2 receptor subunit alpha
3560 aldesleukin; denileukin diftitox IL2RB Interleukin-2 receptor subunit beta
3561 aldesleukin; denileukin diftitox IL2RG Cytokine receptor common subunit gamma
3569 siltuximab IL6 Interleukin-6
3614 thioguanine IMPDH1 Inosine-5'-monophosphate dehydrogenase 1
3615 thioguanine IMPDH2 Inosine-5'-monophosphate dehydrogenase 2
4067 bosutinib LYN Tyrosine-protein kinase Lyn
4860 forodesine PNP Purine nucleoside phosphorylase
5133 nivolumab; pembrolizumab PDCD1 Programmed cell death protein 1
5241 medroxyprogesterone; megestrol acetate PGR Progesterone receptor
5293 copanlisib; idelalisib PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
5422 fludarabine phosphate; clofarabine; cytarabine; gemcitabine POLA1 DNA polymerase alpha catalytic subunit
5471 mercaptopurine PPAT Amidophosphoribosyltransferase
5682 bortezomib PSMA1 Proteasome subunit alpha type-1
5689 bortezomib PSMB1 Proteasome subunit beta type-1
5690 bortezomib PSMB2 Proteasome subunit beta type-2
5693 ixazomib; carfilzomib; bortezomib PSMB5 Proteasome subunit beta type-5
5696 bortezomib PSMB8 Proteasome subunit beta type-8
5743 celecoxib PTGS2 Prostaglandin G/H synthase 2
5915 alitretinoin; tretinoin RARB Retinoic acid receptor beta
5916 alitretinoin; tretinoin RARG Retinoic acid receptor gamma
6240 hydroxycarbamide; gemcitabine; clofarabine RRM1 Ribonucleoside-diphosphate reductase large subunit
6241 hydroxycarbamide; gemcitabine; clofarabine RRM2 Ribonucleoside-diphosphate reductase subunit M2
6256 alitretinoin; bexarotene RXRA Retinoic acid receptor RXR-alpha
6257 alitretinoin; bexarotene RXRB Retinoic acid receptor RXR-beta
6258 alitretinoin; bexarotene RXRG Retinoic acid receptor RXR-gamma
6751 octreotide SSTR1 Somatostatin receptor type 1
6752 lutetium Lu 177 dotatate; octreotide SSTR2 Somatostatin receptor type 2
6753 octreotide SSTR3 Somatostatin receptor type 3
6754 octreotide SSTR4 Somatostatin receptor type 4
6755 octreotide SSTR5 Somatostatin receptor type 5
7010 cabozantinib TEK Angiopoietin-1 receptor
7067 levothyroxine THRA Thyroid hormone receptor alpha
7068 levothyroxine THRB Thyroid hormone receptor beta
7153 etoposide; valrubicin; teniposide; mitoxantrone; idarubicin; daunorubicin; doxorubicin; etoposide phosphate TOP2A DNA topoisomerase 2-alpha
7280 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB2A Tubulin beta-2A chain
7296 arsenic trioxide TXNRD1 Thioredoxin reductase 1, cytoplasmic
7298 pemetrexed; capecitabine; fluorouracil; floxuridine TYMS Thymidylate synthase
7422 bevacizumab VEGFA Vascular endothelial growth factor A
7525 dasatinib YES1 Tyrosine-protein kinase Yes
8841 chidamide; vorinostat; panobinostat; belinostat; romidepsin HDAC3 Histone deacetylase 3
9734 panobinostat; belinostat; romidepsin HDAC9 Histone deacetylase 9
9759 belinostat; panobinostat; romidepsin HDAC4 Histone deacetylase 4
10013 vorinostat; panobinostat; belinostat; romidepsin HDAC6 Histone deacetylase 6
10014 panobinostat; belinostat; romidepsin HDAC5 Histone deacetylase 5
10038 rucaparib; olaparib; niraparib PARP2 Poly [ADP-ribose] polymerase 2
10039 rucaparib; olaparib PARP3 Poly [ADP-ribose] polymerase 3
10381 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB3 Tubulin beta-3 chain
10382 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB4A Tubulin beta-4A chain
10383 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB4B Tubulin beta-4B chain
51185 thalidomide; lenalidomide; pomalidomide CRBN Protein cereblon
51284 imiquimod TLR7 Toll-like receptor 7
51564 panobinostat; belinostat; romidepsin HDAC7 Histone deacetylase 7
55869 panobinostat; belinostat; romidepsin HDAC8 Histone deacetylase 8
57823 elotuzumab SLAMF7 SLAM family member 7
79885 panobinostat; belinostat; romidepsin HDAC11 Histone deacetylase 11
81027 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB1 Tubulin beta-1 chain
83933 chidamide; panobinostat; belinostat; romidepsin HDAC10 Histone deacetylase 10
84617 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB6 Tubulin beta-6 chain
116447 topotecan TOP1MT DNA topoisomerase I, mitochondrial
203068 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB Tubulin beta chain
347688 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB8 Tubulin beta-8 chain
347733 trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel TUBB2B Tubulin beta-2B chain

'measure.vars' is missing. Assigning all columns other than 'id.vars' columns as 'measure.vars'.
Assigned 'measure.vars' are [pp.10060, pp.10087, pp.10292, pp.10557, ...].

Feature importance extracted from extreme gradient boosting model


Genes with top Tclin scores



Genes with lowest Tclin scores



COSMIC oncogenes vs Antineoplastic drug targets top features based on XGB model
Target set % targets with PPI:HSPA1A % targets with PPI:IL10 % targets with PPI:GAPDHS % targets involved in MAPK1/MAPK3 signaling % targets involved in Influenza Infection % targets involved in transcription from RNA polymerase II promoter median bemegride:ASC zscore median zofenopril:A375 zscore median nitrendipine:EFO27 zscore median expression in LUNG (NCIH1930) median expression in ENDOMETRIUM (HEC265)
COSMIC oncogenes 30.46 32.39 17.09 2.23 1.49 15.75 0.13 0.54 -0.02 7.45 6.35
Antineoplastic drug targets 68.79 69.50 48.94 17.73 0.00 3.55 0.36 0.93 -0.19 2.79 2.36
---
title: "COSMIC oncogenes vs Antineoplastic drug targets comparison"
output: html_notebook
---

###[COSMIC](https://cancer.sanger.ac.uk/cosmic) gene census data set downloaded Jan, 2018.

```{r, echo=F}
library(data.table)
dc.antineo <- fread("../data/drugcentral/antineoplastic.tsv", header = F, sep = "\t", quote = "\"", col.names = c("struct_id", "drug_name", "target_id", "component_id", "accession", "swissprot", "symbol", "ncbi_gene_id"))
gene2drug <- dc.antineo[, .(drugs = paste0(drug_name, collapse = "; ")), by = ncbi_gene_id]
cosmic <- fread("../data/cosmic/cancer_gene_census.csv", header = T, sep = ",", quote = "\"")
setnames(cosmic, "Entrez GeneId", "ncbi_gene_id")
cosmic <- merge(cosmic, gene2drug, by.x = "ncbi_gene_id", by.y = "ncbi_gene_id", all.x = T, sort = F)
cosmic.only <- cosmic[is.na(drugs), uniqueN(ncbi_gene_id)]
cosmic.tclin <- cosmic[!is.na(drugs), uniqueN(ncbi_gene_id)]
```

***

```{r, results='asis', echo=F}
library(knitr)
options(knitr.kable.NA = '-')
kable(cosmic[, .(ncbi_gene_id, `Gene Symbol`, `Tumour Types(Somatic)`, drugs)][order(drugs, `Gene Symbol`)], caption = sprintf("COSMIC gene census list. Total genes %d, COSMIC genes mapped to antineoplastic drug targets %d", cosmic[, .N], cosmic.tclin), format = 'pandoc')
```

***

```{r, echo=F, results="asis"}
dc.only <- dc.antineo[!ncbi_gene_id %in% cosmic[, ncbi_gene_id]]
dc.only <- dc.only[, .(drugs = paste0(drug_name, collapse = "; ")), by = ncbi_gene_id]
dc.only <- merge(dc.only, protein[, .(gene_id, symbol, name)], by.x = "ncbi_gene_id", by.y = "gene_id", all.x = T)
kable(dc.only, format = 'pandoc', caption = "Antineoplastic drug targets only")
```


***


```{r, echo=F}
library(xgboost)
library(xgboostExplainer)
dt <- readRDS("../data/input/cosmic_vs_dc.rds")
dt <- dt[subset == "train"]
sumpos <- dt[Y == "pos", .N]
sumneg <- dt[Y == "neg", .N]
model.param <- list(max_depth = 7, eta = 0.1, gamma = 0.01, min_child_weight = 0, subsample = 1, colsample_bytree = 0.8, objective = "binary:logistic", scale_pos_weight = sumneg/sumpos)
X <- data.matrix(dt[, -c("Y", "id1", "subset")])
y <- ifelse(dt[, Y] == "pos", 1, 0)
dtrain <- xgb.DMatrix(X, label = y)
model <- xgb.train(params = model.param, data = dtrain, nrounds = 58, verbose = 1, nthread = 4)
pred <- predict(model, dtrain)
meta <- dt[, .(id1, Y)]
meta[, pred.prob := pred]
library(RPostgreSQL)
conn <- dbConnect(PostgreSQL(), user = "oleg", dbname = "metap")
protein <- dbGetQuery(conn, "select ncbi.protein_id,protein.symbol,protein.accession,gene_id,protein.name from protein,ncbi where ncbi.protein_id = protein.protein_id and tax_id=9606")
dbDisconnect(conn)
rm(conn)
setDT(protein)
protein <- unique(protein, by = "protein_id")
meta <- merge(meta, protein, by.x = "id1", by.y = "protein_id", all.x = T, sort = F)
explainer <- buildExplainer(xgb.model = model, type = "binary", base_score = 0.5, n_first_tree = model$niter - 1, trainingData = dtrain)
pred.breakdown <- explainPredictions(xgb.model = model, explainer = explainer, data = dtrain)
setnames(meta, "id1", "protein_id")
pred.breakdown[, `:=`(protein_id = meta$protein_id, accession = meta$accession)]
pred.breakdown <- melt(pred.breakdown, id.vars = c("protein_id", "accession"), variable.name = "feature", value.name = "log.odds", variable.factor = F, value.factor = F, verbose = T)
pred.breakdown <- pred.breakdown[log.odds != 0.0]
feature.name.long <- readable.feature.names(pred.breakdown[, feature])
pred.breakdown[, feature.long := feature.name.long]
pred.breakdown <- merge(pred.breakdown, protein[, .(protein_id, symbol)], by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)
```

***

###Feature importance extracted from extreme gradient boosting model
```{r, echo=F, fig.align="center", fig.width=10}
features <- colnames(dt)[4:ncol(dt)]
features.names <- readable.feature.names(features)
imp <- xgb.importance(feature_names = features.names, model = model)
xgb.ggplot.importance(importance_matrix = imp, top_n = 20, n_clusters = 1) + theme_bw() + theme(legend.position = "none", axis.title = element_text(size = 22), axis.text = element_text(size = 14), plot.title = element_text(size = 26)) + ggtitle("Model feature importance")
```

***


### Genes with top Tclin scores
```{r, echo = F, fig.align="center", fig.width=18}
library(waterfalls)
library(ggplot2)
id <- meta[order(-pred.prob)][1, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```

***

```{r, echo = F, fig.align="center", fig.width=18}
id <- meta[order(-pred.prob)][2, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```


***

### Genes with lowest Tclin scores
```{r, echo = F, fig.align="center", fig.width=18}
id <- meta[order(pred.prob)][1, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```


***

```{r, echo = F, fig.align="center", fig.width=18}
id <- meta[order(pred.prob)][2, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```

***

```{r, echo=F, results='asis'}
conn <- dbConnect(PostgreSQL(), user = "oleg", dbname = "metap")
features.dt <- dt[, .(id1, Y)]
sumpos <- features.dt[Y == "pos", .N]
sumneg <- features.dt[Y == "neg", .N]
setnames(features.dt, "id1", "protein_id")

feature.protein_id <- 10557
part1 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id2 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id1=",feature.protein_id))
part2 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id1 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id2=",feature.protein_id))
setDT(part1)
setDT(part2)
setnames(part2, "protein_id1", "p1")
setnames(part2, "protein_id2", "p2")
setnames(part2, "p2", "protein_id1")
setnames(part2, "p1", "protein_id2")
feature.dt <- rbindlist(list(part1, part2), use.names = T, fill = T)
setnames(feature.dt, "combined_score", "PPI:HSPA1A")
features.dt <- merge(features.dt, feature.dt[, .(protein_id2, `PPI:HSPA1A`)], by.x = "protein_id", by.y = "protein_id2", all.x = T, sort = F)

feature.protein_id <- 11097
part1 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id2 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id1=",feature.protein_id))
part2 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id1 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id2=",feature.protein_id))
setDT(part1)
setDT(part2)
setnames(part2, "protein_id1", "p1")
setnames(part2, "protein_id2", "p2")
setnames(part2, "p2", "protein_id1")
setnames(part2, "p1", "protein_id2")
feature.dt <- rbindlist(list(part1, part2), use.names = T, fill = T)
setnames(feature.dt, "combined_score", "PPI:IL10")
features.dt <- merge(features.dt, feature.dt[, .(protein_id2, `PPI:IL10`)], by.x = "protein_id", by.y = "protein_id2", all.x = T, sort = F)

feature.protein_id <- 9340
part1 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id2 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id1=",feature.protein_id))
part2 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id1 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id2=",feature.protein_id))
setDT(part1)
setDT(part2)
setnames(part2, "protein_id1", "p1")
setnames(part2, "protein_id2", "p2")
setnames(part2, "p2", "protein_id1")
setnames(part2, "p1", "protein_id2")
feature.dt <- rbindlist(list(part1, part2), use.names = T, fill = T)
setnames(feature.dt, "combined_score", "PPI:GAPDHS")
features.dt <- merge(features.dt, feature.dt[, .(protein_id2, `PPI:GAPDHS`)], by.x = "protein_id", by.y = "protein_id2", all.x = T, sort = F)

pert.id <- "3013"
cell.id <- "ASC"
signature <- dbGetQuery(conn, paste0("select protein_id,zscore from lincs where cell_id = '",cell.id,"' and pert_id = '",pert.id,"' and protein_id in (",paste0(features.dt[, protein_id], collapse = ","),")"))
setDT(signature)
setnames(signature, "zscore", "bemegride:ASC")
features.dt <- merge(features.dt, signature, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

pert.id <- "2866"
cell.id <- "A375"
signature <- dbGetQuery(conn, paste0("select protein_id,zscore from lincs where cell_id = '",cell.id,"' and pert_id = '",pert.id,"' and protein_id in (",paste0(features.dt[, protein_id], collapse = ","),")"))
setDT(signature)
setnames(signature, "zscore", "zofenopril:A375")
features.dt <- merge(features.dt, signature, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

pert.id <- "1947"
cell.id <- "EFO27"
signature <- dbGetQuery(conn, paste0("select protein_id,zscore from lincs where cell_id = '",cell.id,"' and pert_id = '",pert.id,"' and protein_id in (",paste0(features.dt[, protein_id], collapse = ","),")"))
setDT(signature)
setnames(signature, "zscore", "nitrendipine:EFO27")
features.dt <- merge(features.dt, signature, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

tissue <- "LUNG"
cell.id <- "NCIH1930"
expression <- dbGetQuery(conn, sprintf("select protein_id,expression from ccle where tissue = '%s' and cell_id = '%s' and protein_id in (%s)", tissue, cell.id, paste0(features.dt[, protein_id], collapse = ",")))
setDT(expression)
setnames(expression, "expression", "LUNG (NCIH1930)")
features.dt <- merge(features.dt, expression, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

tissue <- "ENDOMETRIUM"
cell.id <- "HEC265"
expression <- dbGetQuery(conn, sprintf("select protein_id,expression from ccle where tissue = '%s' and cell_id = '%s' and protein_id in (%s)", tissue, cell.id, paste0(features.dt[, protein_id], collapse = ",")))
setDT(expression)
setnames(expression, "expression", "ENDOMETRIUM (HEC265)")
features.dt <- merge(features.dt, expression, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

reactome.id <- "R-HSA-168254"
reactome.name <- "Influenza Infection"
reactome <- dbGetQuery(conn, sprintf("select protein_id,reactome_id from reactomea where reactome_id = '%s'", reactome.id))
setDT(reactome)
setnames(reactome, "reactome_id", reactome.name)
features.dt <- merge(features.dt, reactome, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

go.id <- "GO:0006366"
go.name <- "transcription from RNA polymerase II promoter"
go <- dbGetQuery(conn, sprintf("select protein_id,go_id from goa where go_id = '%s'", go.id))
setDT(go)
setnames(go, "go_id", go.name)
features.dt <- merge(features.dt, go, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

summary.dt <- features.dt[!is.na(`PPI:HSPA1A`), .(`% targets with PPI:HSPA1A` = .N), by = Y]
summary.dt <- merge(summary.dt, features.dt[!is.na(`PPI:IL10`), .(`% targets with PPI:IL10` = .N), by = Y], by.x = "Y", by.y = "Y")
summary.dt <- merge(summary.dt, features.dt[!is.na(`PPI:GAPDHS`), .(`% targets with PPI:GAPDHS` = .N), by = Y], by.x = "Y", by.y = "Y")
summary.dt <- merge(summary.dt, features.dt[!is.na(`MAPK1/MAPK3 signaling`), .(`% targets involved in MAPK1/MAPK3 signaling` = .N), by = Y], by.x = "Y", by.y = "Y")
summary.dt <- merge(summary.dt, features.dt[!is.na(`Influenza Infection`), .(`% targets involved in Influenza Infection` = .N), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt[Y == "pos", `% targets involved in Influenza Infection` := 0]
summary.dt <- merge(summary.dt, features.dt[!is.na(`transcription from RNA polymerase II promoter`), .(`% targets involved in transcription from RNA polymerase II promoter` = .N), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`bemegride:ASC`), .(`median bemegride:ASC zscore` = median(`bemegride:ASC`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`zofenopril:A375`), .(`median zofenopril:A375 zscore` = median(`zofenopril:A375`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`nitrendipine:EFO27`), .(`median nitrendipine:EFO27 zscore` = median(`nitrendipine:EFO27`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`LUNG (NCIH1930)`), .(`median expression in LUNG (NCIH1930)` = median(`LUNG (NCIH1930)`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`ENDOMETRIUM (HEC265)`), .(`median expression in ENDOMETRIUM (HEC265)` = median(`ENDOMETRIUM (HEC265)`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt[, `% targets with PPI:HSPA1A` := ifelse(Y == "pos", `% targets with PPI:HSPA1A`/sumpos*100,`% targets with PPI:HSPA1A`/sumneg*100)]
summary.dt[, `% targets with PPI:IL10` := ifelse(Y == "pos", `% targets with PPI:IL10`/sumpos*100,`% targets with PPI:IL10`/sumneg*100)]
summary.dt[, `% targets with PPI:GAPDHS` := ifelse(Y == "pos", `% targets with PPI:GAPDHS`/sumpos*100,`% targets with PPI:GAPDHS`/sumneg*100)]
summary.dt[, `% targets involved in MAPK1/MAPK3 signaling` := ifelse(Y == "pos", `% targets involved in MAPK1/MAPK3 signaling`/sumpos*100,`% targets involved in MAPK1/MAPK3 signaling`/sumneg*100)]
summary.dt[, `% targets involved in Influenza Infection` := ifelse(Y == "pos", `% targets involved in Influenza Infection`/sumpos*100,`% targets involved in Influenza Infection`/sumneg*100)]
summary.dt[, `% targets involved in transcription from RNA polymerase II promoter` := ifelse(Y == "pos", `% targets involved in transcription from RNA polymerase II promoter`/sumpos*100,`% targets involved in transcription from RNA polymerase II promoter`/sumneg*100)]
summary.dt[, Y := ifelse(Y == "pos", "Antineoplastic drug targets", "COSMIC oncogenes")]
setnames(summary.dt, "Y", "Target set")

dbDisconnect(conn)
rm(conn)
kable(summary.dt, caption = "COSMIC oncogenes vs Antineoplastic drug targets top features based on XGB model", format = 'pandoc', digits = 2)
```

